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and FLB (positive control) on the reduction of the 
bone loss 
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Figure 6.6  Histological appearance at 28 days of the apical region 
between enamel and alveolar bone of the rat’s lower 
incisor: (A) Normal mandible from the non-induced 
control group (group 1) showing intact alveolar bone 
(a) and enamel (e) without any signs of resorption; (B) 
and (D), non-treated group (group 2) and positive 
control (group 4), respectively, showing accentuated 
cellular infiltration and destruction of alveolar bone 
(a) as indicated with the red arrows; (D) test group 
(group 3), showing discrete cell influx and almost 
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PEMBANGUNAN DAN PENILAIAN SISTEM NANOGEL YANG 




Periodontitis sangat berleluasa dan merupakan salah satu penyakit pergigian 
utama yang memberi kesan kepada berjuta manusia di seluruh dunia. Bakteria gram 
negatif anaerob dan toksinnya telah dikenalpasti sebagai penyebab utama penyakit ini. 
Banyak sistem penghantaran drug setempat telah dicadangkan, tetapi fokus utama 
kebanyakannya ialah membunuh mikrob penyebab dan bukannya penyasaran 
keradangan yang memainkan peranan penting dalam etiologi penyakit. Lebih-lebih 
lagi, terdapat kesukaran untuk mengakses poket periodontal dan mencapai masa 
kediaman yang mencukupi oleh sistem-sistem sedia ada, oleh itu menjadikan sistem-
sistem sedia ada hanya sebahagiannya berjaya. Oleh itu, matlamat kajian ini adalah 
untuk membangunkan dan menilai suatu nanogel (NG) bioserasi yang baru yang 
dimuatkan bersama dengan triclosan (TCS) dan flurbiprofen (FLB) untuk rawatan 
periodontitis intra-poket yang berkesan. TCS dan FLB merupakan sebatian berhablur 
dan tidak larut air. Sifat ini menghadkan penghantarannya dalam bentuk tulen ke 
dalam poket periodontal, maka wajar diformulasikan dalam sistem nanopartikulat. 
Kaedah HPLC, kajian keserasian, dan nanopartikel (NP) dan NG telah dibangunkan. 
Formulasi-formulasi telah dicirikan dengan ekstensif dengan menggunakan mikroskop 
elektron pengimbasan (SEM), mikroskop elektron transmisi (TEM), saiz partikel, 
indeks polidispersiti (PDI), keupayaan zeta, kalorimetri pengimbasan pembezaan 
(DSC), difraksi serbuk sinar-X (XRPD), spektroskopi inframerah fourier transform 
(FTIR), reologi, pembengkakan, pelepasan in vitro, kestabilan dan kajian in vivo. 
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Kaedah HPLC yang dibangunkan berjaya memencilkan dan mengkuantifikasikan  
TCS dan FLB pada masa retensi (tR) TCS dan FLB pada 12.5 min dan 10.1 min 
masing-masing. Hasil kajian keserasian mencadangkan ketiadaan ketakserasian 
farmaseutikal antara semua komponen dipilih. Penggunaan perisian Design-Expert® 
dalam pembangunan NP membantu dalam mengenal pasti atribut kualiti kritikal untuk 
formulasi NP yang dimuatkan TCS. NP yang dimuatkan TCS yang teroptimum telah 
diikatsilang kepada hidrogel chitosan (CS) yang dimuatkan FLB yang menghasilkan 
NG yang dimuatkan dengan TCS dan FLB. Kandungan drug TCS dan FLB dalam NG 
ialah 93.67 ± 3.51 dan 96.33 ± 2.08% masing-masing. NG yang dimuatkan TCS dan 
FLB mempunyai saiz partikel dan PDI 313.62 ± 66.60 nm dan < 0.3, masing-masing. 
SEM dan TEM menunjukkan bahawa kebanyakan NG berbentuk sfera. Secara fizikal, 
DSC dan XRPD menunjukkan perubahan dalam bentuk pepejal drug-drug di dalam 
NG. Tambahan lagi, FTIR menunjukkan interaksi drug-polimer yang minima dalam 
formulasi NG yang dibangunkan. Daya bioadhesif  NG yang dibangunkan didapati 
sebanyak 137.22 ± 5.05 g. Kajian pelepasan drug in vitro dari sistem NG menunjukkan 
pelepasan panjang dan cepat untuk TCS dan FLB, masing-masing. Hal ini disebabkan 
enkapsulasi TCS dalam NP poly-ε-caprolactone (PCL), dan FLB dalam hidrogel CS 
yang digunakan sebagai pembawa NP yang boleh dihakis dalam keadaan berasid air 
liur simulasi pada 37 °C. Hasil kajian antimikrob mengesahkan aktiviti antimikrob NG 
terhadap kedua-dua bakteria gram-negatif dan gram-positif.  Kajian in vivo dalam tikus 
periodontitis yang disebabkan oleh ligatur menunjukkan peningkatan pertumbuhan 
tulang alveolar yang luar biasa dan kesan anti-radang yang ditingkatkan dalam NG 
yang dibangunkan. Oleh itu, NG yang dimuatkan TCS dan FLB yang telah 
dibangunkan didapati berpotensi untuk rawatan periodontitis dengan berkesan.  
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DEVELOPMENT AND EVALUATION OF NANOGEL SYSTEM LOADED 




Periodontitis is a highly prevalent major dental disease that affects millions of 
people around the globe. Anaerobic gram-negative bacteria and its toxins have been 
strongly implicated as a prime cause of the disease. A great number of local drug 
delivery systems have been proposed, but they were mainly made to focus on killing 
the causative microbes rather than also targeting the inflammation which also plays a 
significant role in the aetiology of the disease. Moreover, there is difficulty in 
accessing the periodontal pocket and attaining adequate residence time by these 
systems, hence being only partially successful. Therefore, the aim of this study was to 
formulate and evaluate a novel biocompatible nanogel (NG) co-loaded with triclosan 
(TCS) and flurbiprofen (FLB) for effective intra-pocket treatment of periodontitis. 
TCS and FLB are highly crystalline compounds and practically insoluble in water. 
These properties restrict delivery of their pure forms into the periodontal pocket, hence 
warranted their formulation into a nanoparticulate system. HPLC method 
development, compatibility study, nanoparticles (NPs) and NG development were 
performed. The formulations were extensively characterised by scanning electron 
microscopy (SEM), transmission electron microscopy (TEM), particle size, 
polydispersity index (PDI), zeta potential, differential scanning calorimetry (DSC), X-
ray powder diffraction (XRPD), fourier transform infrared spectroscopy (FTIR), 
rheology, swelling, erosion, bioadhesion, in vitro release, antimicrobial, stability and 
in vivo studies. The developed HPLC method was able to successfully separate and 
quantify TCS and FLB at retention times (tR) of 12.5 and 10.1 min, respectively. The 
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findings from the compatibility study suggested lack of pharmaceutical 
incompatibility between all the selected components. Design-Expert® software which 
was used in the design and optimisation of NPs has helped in identifying critical 
quality attributes that led to the development of optimised TCS-loaded NPs. The 
optimised TCS-loaded NPs were physically crosslinked with FLB-loaded chitosan 
(CS) hydrogel which resulted in TCS and FLB-loaded NG. Drug content of the loaded 
TCS and FLB in the NG was found to be 93.67 ± 3.51 and 96.33 ± 2.08 %, respectively. 
The TCS and FLB-loaded NG exhibited particle size and PDI of 313.62 ± 66.60 nm 
and < 0.3, respectively. SEM and TEM displayed the NG mostly in spherical shape. 
Physically, DSC and XRPD revealed a change in the solid state of the drugs in the NG. 
Moreover, FTIR indicates minimal drug-polymer interaction in the developed NG 
formulation. Bioadhesive force of the developed NG was found to be 137.22 ± 5.05 g. 
In vitro drug release study from the NG system displayed sustained and rapid release 
of TCS and FLB, respectively. This was mainly due to the encapsulation of TCS in the 
poly-ε-caprolactone (PCL) NPs, and FLB in the CS hydrogel which was used as the 
NPs’ carrier that could be eroded in an acidic condition of simulated saliva at 37 °C. 
The result of the antimicrobial study confirmed the antimicrobial activities of the NG 
against both gram-negative and gram-positive bacteria.  In vivo study on the ligature-
induced periodontitis rats revealed remarkable alveolar bone regeneration and anti-
inflammatory effects of the developed NG. Thus, the formulated TCS and FLB-loaded 






GENERAL INTRODUCTION AND LITERATURE REVIEW 
1.1 Background of Study 
1.1.1 Periodontal Disease 
The term “periodontal disease”, also known as gum disease, refers to the common 
inflammatory pathological conditions that affects the structures of periodontium such 
as gums (gingiva), periodontal ligament, alveolar bone and cementum (Aminu and 
Toh, 2017; Jain et al., 2008; Page and Kornman, 1997; Schwach-Abdellaoui et al., 
2000). The disease is a major dental illness that affects millions of people around the 
globe. A study published in Lancet in 2005 revealed that up to 90% of the world 
population might be affected by periodontal disease (Pihlstrom et al., 2005). Similarly, 
a recent study that was published in 2017 indicated that the disease might be the most 
common disease of human beings and its global burden has increased by more than 
50% from the year 1990 to 2010 (Tonetti et al., 2017). In Malaysia, the 2010 report of 
the National Oral Health Survey of Adults revealed that about 94% of all Malaysian 
dentate adults have some kind of periodontal diseases (Abdulaziz, 2014). The main 
categories of periodontal disease are gingivitis and periodontitis. 
 
1.1.1(a)  Gingivitis 
At the early stage of periodontal disease, a condition called gingivitis will manifest, 
where the bacterial plaque and tartar will build up and trigger a reaction that causes 
gums to become swollen and reddish especially at the margins, and may bleed during 
brushing, mostly as a result of poor oral hygiene (Cochran, 2008; Mizrahi and Domb, 
2008; Tanner, 2015). Gingivitis is the mildest form of periodontal disease, and it is 
very common and readily reversible by simple oral hygiene. The symptoms of 
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gingivitis are less pronounced in many cases, and it may even go unnoticed, so, many 
individuals neglect to treat it. Left untreated, gingivitis may gradually transform into 
irreversible periodontitis (an advanced form of periodontal disease) (Kim and Amar, 
2006). Studies have shown that gingivitis always appears to precede periodontitis 
(Albandar and Rams, 2002; Mizrahi and Domb, 2008).  
 
1.1.1(b)  Periodontitis 
Periodontitis is a prevalent dental inflammatory disorder that affects the soft tissue, as 
well as bone that surrounds and supports the tooth. The word "periodontitis" originates 
from the Greek terms, i.e., peri-, -odont and -itis referring to "around", "tooth" and 
"inflammation", respectively. Therefore, its literal meaning is "inflammation around 
the tooth" (European Federation of Periodontology, 2018; MedicineNet.com, 2018; 
Nordqvist, 2018). Anaerobic gram-negative bacteria and its toxins have been strongly 
implicated for causing the disease (Aminu and Toh, 2017; Jain et al., 2008; Page and 
Kornman, 1997). Some of the identified members of microbiota that were associated 
with periodontitis are Porphyromonas gingivalis, Prevotella intermedia, Treponema 
denticola, Campylobacter rectus, Aggregatibacter (Actinobacillus) 
actinomycetemcomitans, Eubacterium nodatum, Tannerella forsythia, Prevotella spp., 
Peptostreptococcus micros, Streptococcus intermedius, and Fusobacterium nucleatum 
(Lakshmyya Kesavalu et al., 2007; Tanner, 2015). Additionally, host-mediated 
responses have also been found to be involved in the pathogenesis of the disease (Cai 
et al., 2008; Page and Kornman, 1997). It is well established that the inflammatory and 
immune responses play a critical role in the overall aetiology of periodontitis, through 
several host-related intrinsic or induced factors which causes the body to turn on itself 
resulting in serious injury. Pro-inflammatory mediators and cytokine networks such as 
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cyclooxygenase enzymes (which lead to development of prostaglandins, especially 
prostaglandin E2), interleukin (IL)-1, leukaemia inhibitory factor, tumour necrosis 
factor-alpha (TNF-a) and oncostatin M have been found to play essential roles in this 
process (Cai et al., 2008; Cochran, 2008; Graves and Cochran, 2003; Lerner, 2006). 
The accumulation of microbiota triggers the release of these mediators, which in turn 
stimulate the breakdown of connective tissue and destruction of periodontium. Figure 
1.1 shows a comparison between a healthy tooth and periodontitis. 
 
 
Figure 1.1: A comparison between healthy and diseased tooth. 
Periodontal pocket has developed on the diseased tooth. The 
figure was adopted from (Zuerlein, 2018) 
 
During the progression of periodontitis, the epithelial and subepithelial 
connective tissue of the gingiva detaches from the tooth surface leading to an unusual 
depth of the gingival sulcus termed as ‘periodontal pocket’ (Vyas et al., 2000). This 
pocket provides an ideal medium for the proliferation of gram-negative anaerobic 
pathogenic bacteria. Thus, periodontitis is characterised by inflammation of the 
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structures adjacent to the teeth that extends deep into the tissues and causes loss of 
supporting connective tissue and alveolar bone (Pihlstrom et al., 2005). Without proper 
treatment, the bacteria’s tartar and calculus will greatly build up on the teeth surfaces 
and in the periodontal pockets, and the pockets may perforate up to the periodontal 
ligament, resulting in loosening and loss of teeth as a consequence (Darveau, 2010; 
Jain et al., 2008).  
There are several other risk factors besides poor oral hygiene that may directly 
or indirectly contribute to the development of periodontitis. Some of these important 
risk factors are: certain systemic diseases; smoking or chewing tobacco; older age; 
genetics; hormonal changes (in pregnancy or menopause) (Mayo Foundation for 
Medical Education and Research, 2018); malnutrition (including deficiency in vitamin 
C) (Nishida et al., 2000); excessive alcohol consumption (Pitiphat et al., 2003); stress 
(Genco et al., 1999); and medications such as steroids, anti-epileptic and 
chemotherapeutic drugs (Ireland Dental Health Foundation, 2018; Petersen and 
Ogawa, 2012; U.S. National Institute of Dental and Craniofacial Research, 2013).  
 
1.1.2 The Potential Relationship between Periodontitis and Systemic Health 
Many authors have reported studies that associated periodontitis to various systemic 
diseases (Ameet M. et al., 2013; Cullinan et al., 2009; Garcia et al., 2001). A review 
article summarised evidence linking periodontal diseases with cardiovascular 
disorders such as atherosclerosis, ischemic heart disease, coronary heart disease and 
myocardial infarction. Epidemiologic studies demonstrated these potential links 
through periodontal infections (Dhadse et al., 2010). Researchers have identified some 
common pathogens associated with periodontal infection in cardiovascular areas such 
as atherosclerotic, carotid, coronary and aortic plaques (Cairo et al., 2004; Iwai et al., 
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2005). Several other studies have also demonstrated positive correlations between 
these two diseases. 
Periodontitis has also been found to be a manifestation of other systemic 
diseases, especially in immuno-compromised patients such as those with human 
immunodeficiency virus (HIV) and those suffering from general infection (Petersen 
and Ogawa, 2012). Therefore, patients diagnosed with periodontitis are likely to be at 
higher risk of developing certain systemic diseases because the lesions arising from 
the disease have been recognised as reservoirs for the continuous systemic spread of 
anaerobic gram-negative bacteria, its antigens and some pro-inflammatory mediators 
like cytokines. Significant associations between periodontitis and diabetes mellitus, 
osteoporosis, preterm low birth weight and some other diseases have also been 
discovered (American Academy of Periodontology, 2018; Cullinan et al., 2009; Kim 
and Amar, 2006). All these findings strongly suggest that oral health may be an 
important indicator of systemic health.  
Therefore, these studies imply the importance of effective interventional 
periodontal care that may improve not only oral health but also the overall systemic 
health. Hence, researchers must continue to explore novel treatment strategies for 
enhancing the therapeutic outcomes of periodontitis.    
 
1.2 Statement of the Problem 
Delivering a therapeutic agent to the targeted site has been a major hurdle in the 
treatment of periodontitis. The drawback of most conventional periodontal drug 
delivery systems after administration is the poor penetration of drug into the junctional 
epithelium (Aminu et al., 2017, 2013). Administering systemic medication such as 
antibiotics may serve as a vital supplement to scaling and root planning in the treatment 
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of periodontitis. For example, tetracycline, metronidazole, and amoxicillin either alone 
or in their combination have been employed to target a broad range of bacteria in the 
treatment of the disease  (Addy and Langeroudi, 1984; Chaturvedi et al., 2012; Yadav 
et al., 2015). However, systemic antibiotic therapy is mostly unspecific and may lead 
to the inhibition of beneficial microflora in the gastro-intestinal tract (Bourrain et al., 
2013; Martínez, 2017). Furthermore, frequent use of these drugs may lead to the 
development of resistance. Therefore, systemic antibiotics are now seldom used for 
the treatment of periodontitis because of its drawbacks such as: gastrointestinal 
intolerance, inadequate antibiotic concentration at the site of periodontal pocket, rapid 
decline of the plasma antibiotic concentration to subtherapeutic levels, requiring 
frequent dosing, lack of patient compliance, and hypersensitivity (Jain et al., 2008; 
Kataria et al., 2014).  
Similarly, conventional local drug delivery systems of periodontitis are 
characterised by limited effectiveness, poor biodistribution, and lack of selectivity 
(Wilczewska et al., 2012). A great number of local drug delivery devices for this 
disease have been proposed (Table 1.1), but unfortunately, the difficulty in accessing 
the periodontal pocket has rendered these approaches only partially successful (Kashi 
et al., 2012). These apparent disadvantages have evoked an interest in the development 
of more effective intra-pocket drug delivery systems for the treatment of periodontitis. 
Since the disease is primarily confined in periodontal pockets, effective localised intra-











Polymer(s) used References 
Microparticles Metronidazole Cross-linked CS (Pichayakorn and 
Boonme, 2013) 
Ofloxacin PLGA (Jamal et al., 2012) 
Doxycycline PLGA + PCL (Shanmuganathan et al., 
2008) 
 Tetracycline PLGA (Esposito et al., 1997) 
Chlorhexidine PLGA (Yue et al., 2004) 
Films Ciprofloxacin & 
Diclofenac 
CS (Ahmed et al., 2009) 
Chlorhexidine Ethyl cellulose (Hirschfeld et al., 1984) 
Metronidazole CS & PCL (El-Kamel et al., 2007) 
Minocycline PCL (Kyun et al., 1990) 
Chips Chlorhexidine Cross-linked hydrolysed 
gelatin & glycerin 
(Mızrak et al., 2006) 
Chlorhexidine PLGA (Yue et al., 2004) 
Strips Chlorhexidine Acrylic polymer (Addy and Langeroudi, 
1984) 
Metronidazole Hydroxypropyl cellulose (Wade et al., 1992) 
Doxycycline Hydroxypropylmethylcellulose 
and methylcellulose 
(Taner et al., 1994) 
Gels Tetracycline HCl 
& Metronidazole 
benzoate 
CS (Popa et al., 2013) 
Metronidazole CS (Akncbay et al., 2007) 
Fibers Tetracycline PCL & cellulose acetate 
propionate 
(Raheja et al., 2013) 




PLGA & ethyl cellulose (Bromberg et al., 2001) 











PLA and PLGA (Gad et al., 2008) 
Micelles Triclosan Micelles of poloxamine T1107 (Chiappetta et al., 2008) 
Poly (lactic-co-glycolic acid) (PLGA); poly lactic Acid (PLA); poly-ε-caprolactone (PCL); chitosan 
(CS) 
 
1.3 Nanoparticles in Periodontitis Therapy 
Some important solutions to the problems discussed in Section 1.2 above came through 
the recent advancement and innovations in nanotechnology. Nanotechnology was 
described to comprise particles or structures that fall within the size range of 1 to 100 
nm in diameter (US National Nanotechnology Initiative, 2017). However, from the 
pharmaceutical viewpoint, all particles or structures that are less than 1 µm in diameter 
are recognised as nanoparticles (NPs) (Williams III and Vaughn, 2007).  
NPs are complex mixtures which involved interactions of two or more different 
type of components. In most cases, the exact composition of the NPs’ structure, both 
surface and internal, is intimately related to their intended applications and commonly 
comprises multilayers and/or multiphase packed with APIs to provide the desired 
functions (Christian et al., 2008; Naito et al., 2018). These layers can be of two or three 
types, i.e. (1) a surface which can be functionalised, (2) a shell which may be 
intentionally added and it’s often chemically different from the core of the NP, and (3) 
a core which is essentially the inner part of the NP and commonly associated with its 
fundamental properties that results to most of its applications (Christian et al., 2008; 
Khan et al., 2017). 
The applications of NPs in modern medicine has a profound positive influence 
on pharmaceutical and biomedicines by contributing to better paths of healthcare 
delivery, ranging from disease prevention to ultimate treatment (Sahu et al., 2017). 
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There is growing interest in nanoparticulate systems which is attributable to the search 
for alternatives to some of the conventional drug delivery systems that lack desirable 
effectiveness. In recent years, formulation scientists and researchers have been deeply 
involved in investigating novel delivery systems which would enhance the 
pharmacological action of drugs at the same time decreasing its toxic side effects (Ding 
et al., 2013; Thassu et al., 2007). One outcome is the use of NPs that can provide site-
specific or targeted drug delivery combined with optimal drug release profiles. Studies 
have shown that NPs has excellent potentials as drug carriers for effective delivery of 
therapeutic agents into the periodontal pockets (Piñón-Segundo et al., 2005). The 
advantages of NPs which include small size, site specificity, high dispersibility in 
aqueous medium, better stability during storage as compared to liposomes, controlled 
release rate, feasibility of incorporating both hydrophilic and hydrophobic substances, 
high carrier capacity, and improved dissolution and bioavailability, make them suitable 
candidates for delivering drugs into the periodontal pockets in the treatment of 
periodontitis. In addition, these systems may reduce the frequency of drug 
administration which in turn may improve patient compliance. It also has the potential 
to provide a uniform release of active agent over an extended period thus resulting in 
a high benefit to low-risk ratio as compared to conventional dosage forms (Pramod et 
al., 2014; Puri and Puri, 2013).  
Researchers have studied that NPs can transport active pharmaceutical 
ingredients (APIs) across the junctional epithelium and can also be a potential intra-
pocket carrier system for the delivery of APIs to the periodontal pocket. Piñón-
Segundo et al. (2005) developed and characterised triclosan (TCS)-loaded NPs as a 
novel delivery system for the treatment of periodontitis, using emulsification-diffusion 
method. In their study, polylactic (PLA), poly(lactic-co-glycolic acid) (PLGA) and 
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cellulose acetate phthalate were used as carrier polymers, and poly(vinyl alcohol) 
(PVAL) as a stabiliser to prepare the NPs.  Their results showed the NPs were less 
than 500 nm, with entrapment efficiency (EE) above 63.8% for all batches. An in-vivo 
study in dogs with experimental periodontitis (EP) suggested that TCS-loaded NPs 
were able to permeate across the junctional epithelium and deliver the loaded TCS, 
which in turn lead to a decrease in gingival inflammation (Piñón-Segundo et al., 2005).  
In a similar development, TCS-loaded poly-ε-caprolactone (PCL) NPs for the 
treatment of periodontal infections was synthesised by Aminu et al. (2013). Box–
Behnken statistical model was used for the design of experiments and optimisation, 
and solvent displacement method for the NPs development. The NPs were 
characterised and evaluated as per their morphology, particle size and distribution, 
polydispersity index, zeta potential, EE and drug loading, differential scanning 
calorimetry (DSC), cell viability assay, in vitro and accelerated stability studies. The 
results revealed that the synthesised NPs are less than 230 nm. The NPs demonstrated 
nearly 100% cell viability in L929 cell lines, which indicated the absence of 
cytotoxicity and hence confirmed its safety. The optimised NPs were mainly spherical 
and exhibited biphasic in vitro release pattern. The study concluded that TCS-loaded 
PCL NPs could serve as a novel colloidal drug delivery system for the treatment of 
periodontal infections (Aminu et al., 2013). 
Osorio and associates designed bioactive and cytocompatible NPs loaded with 
calcium and zinc for the treatment of periodontal disease. The PolymP-n active NPs 
was fabricated with 2-hydroxyethyl methacrylate as the backbone monomer, ethylene 
glycol dimethacrylate as a cross-linker, and methacrylic acid as a functional monomer 
using polymerisation precipitation method. They used scanning electron microscopy 
(SEM) that were attached to an energy dispersive analysis system to evaluate the 
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biomimetic precipitation on polymeric particles after immersion in a simulated body 
fluid for seven days. They also conducted other evaluation studies such as X-ray 
diffraction and cell viability analysis. Results confirmed that calcium and phosphate 
had precipitated on the surfaces of NPs loaded with calcium. Cell viability assays 
indicated that calcium and zinc-loaded NPs have a dose-dependent but very minor 
cytotoxic effect. The authors concluded that the observed less toxic calcium-loaded 
NPs and its ability in promoting precipitation of calcium phosphate deposits might 
offer new strategies for the treatment of periodontal disease (Osorio et al., 2016). 
Kashi and associates prepared minocycline-loaded PLGA NPs for periodontal 
infection treatment, with the aim to improve low EE of hydrophilic drugs. They 
employed different techniques for the preparations of polymeric NPs which include 
nanoprecipitation, single and double solvent evaporation, and ion pairing. The 
resulting NPs were characterised with respect to particle size and size distribution, 
morphology, drug loading and EE, thermal properties, and antibacterial activity. They 
observed that the prepared NPs were spherical with a particle size in the range of 85–
424 nm. The best EE, i.e. 30% of the study was obtained with solid/oil/water ion 
pairing method, hence the method was selected. The minocycline-loaded NPs 
exhibited a minimum bactericidal concentration and minimum inhibitory 
concentration (MIC) which was at least two times lesser than that of the free drug, 
while its in vitro antibacterial activity was higher than the free drug (Kashi et al., 2012). 
In another similar investigation, a team of researchers prepared and 
characterised minocycline-loaded poly(ethylene glycol)–poly(lactic acid) (PEG-PLA) 
NPs for enhancing localised treatment of chronic periodontitis in beagle dogs. They 
used emulsion/solvent evaporation technique to prepare the NPs. The minocycline-
loaded NPs were subjected to in vitro release and in vivo pharmacokinetics studies of 
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minocycline in phosphate-buffered saline (PBS; 0.01 M, pH 7.4) and gingival 
crevicular fluid of beagle dogs with induced periodontitis, respectively. Results 
showed that the minocycline-loaded NPs were mainly spherical, with an average 
particle size of 100 nm in diameter, and demonstrated a sustained release characteristic 
of minocycline during in vitro release study. The researchers also observed that the 
prepared NPs have better drug retention in dogs’ gingival crevicular fluid than 
Periocline®, and hence, suggested that minocycline-loaded NPs may be a potential 
drug delivery candidate for the treatment of periodontitis (Yao et al., 2014). 
 
1.4 Nanogels in Periodontitis Therapy 
Incorporation of polymeric NPs into strands of another polymer network such as a 
hydrogel may lead to the formation of an interestingly novel class of dosage form 
called nanoparticles-hydrogel composite or nanogel (NG). As indicated in Figure 1.2, 
NG is a nanoscale multicomponent network that consists of NP structures entwined 
into hydrogel (a three-dimensional, cross-linked hydrophilic polymer network). NG 
has attracted growing interest in recent years as one of the most promising 
nanoparticulate drug delivery systems. This may be due to its unique potential of 
yielding the beneficial characteristics of NPs (as mentioned in Section 1.3) and that of 
hydrogel system (such as hydrophilicity, softness, rubbery, low interfacial tension with 
aqueous medium or biological fluid, and extremely high water content), in a unit 
delivery system (Pérez et al., 2014; Yao et al., 2016). In addition, the size and unique 
surface properties of NG enable them to be involved in more chemical reactions and 
multivalent bioconjugation. NG can also be loaded with a myriad of drugs and 
biomolecules by entrapment or encapsulation due to its structural features. Hence, it 
can be highly useful for delivery of drugs and other bioactive molecules (Bencherif et 
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al., 2009). This drug loading is achieved through self-assembly mechanisms involving 
Van der Waals, electrostatic, and/or hydrophobic interactions between molecules of 
the drug and that of the polymer (Yao et al., 2016).  
 
Figure 1.2: Schematic illustration in 3D of nanoparticles-
hydrogels composite (nanogel), showing how nanoparticles 
are entwined in a hydrophilic polymer network (Wu et al., 
2013) 
 
1.4.1 Advantages of Nanogel as Drug Delivery Systems 
NG can exhibit several advantages when used as drug delivery systems. These 
advantages are:  
a) NG is often biocompatible, biodegradable and bioadhesive (if polymers with such 
features are used in its composition) because of their physical properties’ similarity 
with living tissue 
b) Through the NG, multiple drugs can be loaded and delivered to the targeted site 
with or without chemical cross‑linkage. Non-chemical cross‑linkage loading has 
the benefit of maintaining the original drug activity 
c) NG system can be suitably fabricated for various routes of administration such as 
to the oral cavity which include the periodontal area, parenteral, intra-ocular and 
nasal cavity 
d) NG is easy to produce, handle, and administer 
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e) NG can swell up to more than 30 times of its initial volume, a property embodied 
in hydrogels, hence providing more surface area for accommodation of APIs 
f) NG can enhance solubility as well as pharmacokinetics of the conjugated drugs 
g) NG can be designed to have controlled and sustained release characteristics 
h) NG provides an opportunity for designing both passive and active targeting 
because of its surface nature and molecular size  
i) NG has high stability  
Thus, NG represent a promising carrier system for effective delivery of drugs 
and other biologically active agents (Aminu and Toh, 2017; Moya-Ortega et al., 2012; 
Pérez et al., 2014; Rejinold et al., 2012; Sahu et al., 2017; Yao et al., 2016). 
Studies have shown evidence where NG techniques were employed to develop 
drug delivery systems in which two drugs were loaded in a unit delivery system. 
Researchers from Massachusetts Institute of Technology, USA have carried out a 
study where two drugs were loaded in a mesh-like network of NG. They developed 
PEG-PLA NPs which were suited to carry hydrophobic small-molecules of drug. On 
the other hand, they made a gel with a cellulose polymer suited to carry hydrophilic 
drug and then mixed the two components which resulted in NG (Trafton, 2015). Thus, 
this is important progress in formulation science especially for simultaneous delivery 
of multiple drug substances for the treatment of certain diseases. 
Bako and coworkers (2008) developed nanocomposite biocompatible 
hydrogels (NG) which could be used as a model system for in situ local drug delivery 
devices for treatment of periodontal infections. This NG was composed of NPs, gel 
matrix and chlorhexidine as an antibacterial drug. The researchers initially prepared 
NPs by free radical initiated copolymerisation of monomers which comprises 2-
hydroxyethyl methacrylate and polyethylene glycol dimethacrylate. They used the 
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same monomers to prepare crosslinked gel matrices. Finally, they developed NG by 
mixing NPs, gel matrices and the drug in an aqueous solution by photopolymerisation 
crosslinkage. This integrated gel system showed distinct advantages compared to 
simple hydrogels as a drug delivery system. Based on this study, they concluded that 
in situ polymerisations of hydrogels offers flexibility for local placement of drugs in 
the treatment of periodontal disease (Bako et al., 2008). 
In another study, NG with thermoresponsive properties was prepared and 
characterised. Inverse emulsion polymerisation technique was used for its fabrication 
via cross-linkage of acrylate derivatives of poly(ethylene glycol) and poly(ethylene 
glycol)-bl-poly(propylene glycol)-bl poly (ethylene glycol) copolymers, also known 
as Pluronics®. These synthesised hydrogel-NPs were of a size range of 100 to 500 nm 
and were found to be stable (Missirlis, 2005). 
Fukui et al. (2007) investigated whether cholesterol-bearing pullulan modified 
with amino-groups (CHPNH2) NG could be used as a carrier to introduce quantum 
dots into the periodontal ligament cells that were obtained from a primary culture. The 
CHPNH2 NG was found to form complexes with quantum dots resulting in 
monodisperse hybrid NPs which were able to be delivered into live cells by 
endocytosis in significant quantities. Therefore, the CHPNH2 NG was found to be 
useful as a carrier to introduce quantum dots into periodontal ligament cells in cell 
culture, and it demonstrated feasibility for further characterisation of periodontal 
ligament cells as well as investigation of regenerative processes (Fukui et al., 2007). 
This feature further demonstrates the capacity of the NG system in periodontal therapy. 
In another investigation, doxycycline nano-liposome slow-release NG was 
evaluated for therapeutic effects on an established rat model of periodontitis. The 
biocompatibility of the system was examined by oral perfusion of the sample gel for 
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prolonged observation. The results revealed that doxycycline NG exhibit excellent 
biocompatibility from weight measure and tissue section evaluation. Furthermore, the 
NG system demonstrates the ability to improve periodontitis condition on rats with 
periodontitis defects (Jin et al., 2010). 
Just of recent, Madi and co-researchers prepared and evaluated nanostructured 
doxycycline gel and then compared its anti-inflammatory effectiveness against 
conventional doxycycline gel when used locally as an adjunct to scaling and root 
planning in the treatment of chronic periodontitis. They developed the nanostructured 
doxycycline gel by spray-drying technique, using CS as a matrix polymer and 
polyvinyl alcohol as a stabiliser. This NG, as well as the conventional doxycycline gel, 
were tested on patients suffering from chronic periodontitis that possessed a deep 
periodontal pocket. Results showed that all the tested treatment plans significantly 
reduced the level of inflammatory mediators of the investigated patients. However, 
only doxycycline-loaded NG significantly decreased probing depth when compared 
with the conventional doxycycline gel and placebo CS gel during the study period. The 
researchers concluded that nanostructured doxycycline gel could impart anti-
inflammatory effect when used as an adjunct to scaling and root planning, by 
enhancing clinical parameters as well as inflammatory markers (Madi et al., 2018). 
 
1.5 Rationale of the Present Study 
The oral administration of antibiotics as a therapeutic remedy for the treatment of 
periodontitis is no longer a preferred choice due to the reasons mentioned in Section 
1.2. Local or targeted drug delivery approaches are the best strategy currently being 
adopted for the effective management of periodontal disease. This is because they are 
more favourable as compared to systemic approach, and also because of its site-
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specific delivery, reduction of dosing frequency and gastrointestinal side effects, low 
dose requirement, and bypass of first-pass metabolism effect (Joshi et al., 2016). 
Additionally, local drug delivery approach can provide a safe and effective medium of 
treatment.  
Several researchers have reported nanoparticulate drug delivery approaches in 
which a single drug (mostly antibacterial) were loaded in polymer-based system and 
used for the treatment of periodontitis (Abou Neel et al., 2015; Joshi et al., 2016; Kong 
et al., 2006; Nguyen and Hiorth, 2015). There is little research done on delivery 
approaches where multiple drugs are loaded and delivered into the periodontal pockets. 
The reported approaches suffer from adhesion problem at the periodontal pocket (site 
of action), as they are rapidly flushed away by saliva or during ingestion of food 
substances. Moreover, they mainly focused on neutralising the causative bacteria 
rather than also targeting the pro-inflammation factors. It is well established that 
inflammation is one of the major pathological outcomes of periodontitis (Cai et al., 
2008; Cochran, 2008; Graves and Cochran, 2003; Lerner, 2006; Pihlstrom et al., 2005), 
hence countering it should be one of the primary goals for an ideal treatment strategy. 
Besides causing periodontal tissue destruction, inflammation can also inflict severe 
pain and cause discomfort to the patient. Therefore, by blocking inflammatory 
pathways through the use of non-steroidal anti-inflammatory drugs (NSAIDs), 
periodontitis should be better treated.  This is because NSAIDs can significantly 
decrease the periodontal tissue breakdown, promote healing and regeneration of 
alveolar bone (Vyas et al., 2000).   
As of the time of planning the present study, there was no reported investigated 
study where a nanoparticulate drug delivery system loaded with antimicrobial and anti-
inflammatory agents for the enhancement of therapeutic outcomes of periodontitis. 
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Therefore, to fill in this gap, as well as to address the identified shortcomings 
mentioned above and in Section 1.2, development of a bioadhesive polymeric NG drug 
delivery system that can be effectively delivered and retained for an extended period 
in the periodontal pockets was envisaged. The NG would be developed from NPs and 
hydrogel. Hence, it may possess the essential properties of both systems. This 
developed NG would be loaded with dual therapeutic agents, i.e., antimicrobial and 
anti-inflammatory drugs, in order to simultaneously halt the causative pathogenic 
microbes and the triggered inflammation and pain. This study can be considered as a 
significant contribution in the field of formulation science and dentistry, since up to 
now there are no reported experimental studies which investigated the potential 
benefits of using a NG strategy with antimicrobial and anti-inflammatory effects, as 
an alternative therapeutic remedy for the treatment of periodontitis.  
Therefore, NG was selected as a drug delivery system due to its ability to 
penetrate the gingival sulcus and periodontal pocket, and be retained for a prolonged 
period thereby providing and maintaining an effective drug release rate. The pocket 
allows easy access to the medication delivery tool and dislodgment of its content. The 
environmental conditions of the periodontal pocket, i.e. temperature and acidic pH 
would be used as trigger factors for in situ gelation of the NG, swelling, erosion and 
release of its cargo. This may provide controlled drugs release from the bioadhesive 
polymer matrix, improve the treatment’s effectiveness, reduce the treatment cost, and 
improve patient’s compliance. 
In this work, triclosan (TCS) and flurbiprofen (FLB) were selected as the drugs 
for the intended pharmacological actions, while poly-ε-caprolactone (PCL) and 
chitosan (CS) were the selected polymeric carriers. Kolliphor® P188 (KP) was the 
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selected stabiliser during NPs development. The details of these selected components 
are discussed in the following sections.  
 
1.5.1 Triclosan  
TCS (Figure 1.3) is a non-ionic broad-spectrum antimicrobial agent that has a 
recognised efficacy against several plaque-forming bacteria and has been used 
extensively in various products for more than four decades (Piñón-Segundo et al., 
2005; Rosling et al., 1997a). 
 
 
Figure 1.3: Structure of triclosan (5-chloro-2-(2,4-
dichlorophenoxy) phenol) 
 
Studies showed that the broad spectrum antimicrobial effect of TCS covered a 
wide range of gram-positive and gram-negative bacteria found in the oral cavity 
(Ciancio, 2007; Davies, 2007). The antimicrobial profile of TCS has been reported in 
the literature (Australian National Industrial Chemical Notification and Assessment 
Scheme, 2009; Bhargava and Leonard, 1996; U.S. Food & Drug Administration, 
2008). TCS has been included in several oral health care products such as dentifrices 
and oral rinses due to its efficacy in preventing and reducing bacterial plaque (Jones 
et al., 2000). A review study on the efficacy of TCS in dentifrices revealed that it acts 
as an effective anti-plaque and anti-gingivitis agent in dentifrices, and hence, it is an 
essential drug candidate for the treatment of periodontitis (Gunsolley, 2006). 
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Researchers had demonstrated that TCS reduced the already established supragingival 
plaque and resolved gingival lesions. It also has some in-vitro antiviral and antifungal 
activity (Bhargava and Leonard, 1996; Jones et al., 2000). A study which involved 60 
adult human subjects with recurrent periodontitis was conducted to determine whether 
the use of a dentifrice containing TCS can influence clinical symptoms of the disease 
(Rosling et al., 1997b). The subjects were instructed to use the dentifrice containing 
0.3% TCS for a specified period. Results demonstrated that this dentifrice with TCS 
content reduced bone loss and frequency of deep of periodontal pockets (Rosling et 
al., 1997b). Similar results were obtained when NPs loaded with 9% of TCS was used 
to treat beagle dogs with induced periodontal disease (Piñón-Segundo et al., 2005). 
With solubility of ≤ 0.01 g L-1 at 20 °C, TCS is practically insoluble in the 
water (Aminu et al., 2013; Australian National Industrial Chemical Notification and 
Assessment Scheme, 2009; Bhargava and Leonard, 1996; Scientific Committee on 
Consumer Products of European Commission, 2009; U.S. Food & Drug 
Administration, 2008; Vyas et al., 2000). The drug is also highly crystalline in nature 
(Celebioglu et al., 2014; Scientific Committee on Consumer Products of European 
Commission, 2009; Sweetman, 2009). These properties restrict delivery of pure TCS 
into the periodontal pocket, hence warranted its formulation into a suitable dosage 
form such as nanoparticulate system in order to facilitate its delivery and release at the 
site of action. Several researchers have employed TCS for various antimicrobial 
effects. However, due to its low water solubility and extreme crystallinity, these 
researchers have to prepare NPs formulation of the drug to counter these challenges 
and to enable its delivery to the targeted site of action as well as to improve its 
bioavailability (Davachi and Kaffashi, 2015; Davoodi et al., 2016; Domínguez-
Delgado et al., 2011; Piñón-Segundo et al., 2005; Wais et al., 2018). Therefore, in the 
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present study, TCS will be loaded into polymeric NPs to change it solid state from 
highly crystalline to amorphous, as well as to facilitate its transportation to the 
periodontal pocket for enhancement of its therapeutic effect. 
 
1.5.1(a) Mechanism of Action of Triclosan  
TCS acts by blocking the active site of the enoyl-acyl carrier protein reductase enzyme 
(ENR), an essential enzyme in fatty acid synthesis in bacteria. By blocking the active 
site, TCS inhibits the enzyme and therefore prevents the bacteria from carrying out the 
fatty acid synthesis, which is necessary for building cell membranes and for 
reproduction (Levy et al., 1999; McMurry et al., 1998). TCS is a very potent inhibitor 
of ENR enzyme, and even a small amount can exert powerful antimicrobial action. 
Humans do not have this ENR enzyme and hence are not affected. TCS has long been 
determined to be fairly harmless to humans, thus in classical toxicological terms, it is 
relatively non-toxic to them and other mammals (Glaser, 2004). 
 
1.5.2 Flurbiprofen 
FLB (Figure 1.4) belongs to NSAIDs class of drugs that has been well investigated 
during the last two decades, as modulators of the inflammatory response of the host 
having periodontitis (Heasman et al., 1993; Ribeiro et al., 2012). Studies have revealed 
evidence which indicated that supplementing periodontitis treatment with NSAIDs can 
have a positive effect on the outcome of the therapy (Hersh et al., 1991; Jeffcoat et al., 




Figure 1.4: Structure of flurbiprofen ((±)-2-(2-fluoro-4-
biphenylyl) propionic acid) 
 
FLB, a non-selective cyclooxygenase (COX) enzyme inhibitor (Agrawal et al., 
2016), has been used for the management of periodontitis in both animals and humans 
(Jeffcoat et al., 1988; Williams et al., 1987), and has been found to be efficacious when 
used as a topical rinse or systemic medication (Heasman et al., 1993; Jeffcoat et al., 
1995). FLB blocks the COX enzymes which cause inflammation and pain (Heasman 
et al., 1993). COX enzymes are inflammatory enzymes triggered by cytokines – 
critical immune factors in periodontal disease. The drug is used not only for relieving 
pain in periodontitis but also for slowing the disease process (Jeffcoat et al., 1988). 
Several studies have found FLB to significantly decrease gingival inflammation and 
slow the progression of periodontitis (Howell and Williams, 1993). Similarly, many 
studies have reported the ability of FLB to aid in healing and reduce alveolar bone loss 
in patients with periodontitis, for both surgical and nonsurgical treatment, and these 
successes were evident with both short-term and long-term use of the medication 
(Dicke, 2011; Jeffcoat et al., 1988). However, long-term systemic use of COX enzyme 
inhibitors such as FLB can result in gastrointestinal disturbances (Heasman et al., 
1993; Ribeiro et al., 2012). Because of this reason, topical application of the drug is 
logically favourable in circumventing the gastrointestinal adverse effect of FLB. 
Fortunately, studies have shown that FLB is well absorbed through the gingival tissues 
(Salvi and Lang, 2005). Additionally, an investigation conducted to evaluate the 
effectiveness of topically applied FLB had yielded favourable outcomes by promoting 
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bone gain following nonsurgical therapy of periodontitis (Dicke, 2011; Heasman et al., 
1993). Therefore, in the present study, FLB will not be incorporated in NPs but rather 
directly into the hydrogel system since it is well absorbed on the gingiva. Moreover, 
this may lead to its immediate release after application of the NG formulation in order 
to manage the gingival inflammation and reduce pain arising from the application site. 
The ability to use FLB for local effect reduces concerns of adverse effects and toxicity 
that may arise from long-term ingestion of the drug. Thus, the incorporation of FLB in 
topical formulations for periodontitis treatment may improve their effectiveness. 
 
1.5.3 Combination of Two Drugs for the Treatment of Periodontal Disease 
There are few reported studies which developed drug delivery systems that contained 
two drugs. For example, Popa and co-workers developed chitosan (CS) gel containing 
two antibacterial drugs (tetracycline hydrochloride and metronidazole benzoate) for 
local intra-pocket drug delivery for the treatment of periodontal disease. Based on 
kinetic release and rheological studies’ data, the researchers concluded that 3% w/w 
concentration of CS could offer a base for an optimum modulation in drug dose, and 
its gels are efficient in the local treatment of periodontal disease (Popa et al., 2013). A 
suitable formulation of TCS and FLB combination would be highly desirable for 
periodontal therapy, owing to the therapeutic efficacy of the drugs as discussed in 
Section 1.5.1 and 1.5.2 above. 
 
1.5.4 Poly-ε-caprolactone Polymer 
PCL (Figure 1.5) is a family member of aliphatic polyesters which is highly 
hydrophobic and semi-crystalline in nature, and has been found to be biodegradable, 
biocompatible, having in vitro stability, relatively low cost and having good drug 
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permeability properties (Azimi et al., 2014; Ranjha et al., 2009; Zamani et al., 2010). 
These essential features have led to its applications in drug delivery systems and 
biomedicals such as prosthetics, bandages, and sutures (Azimi et al., 2014; Jayakumar 
and Tamura, 2008).  
 
Figure 1.5: Structure of poly-ε-caprolactone ((1,7)-
polyoxepan-2-one) 
 
PCL is structurally an achiral polymer, a feature that restricts chances of 
modulation of its properties via the structural configuration of polymer chains, and 
therefore, it is highly resistant to chemical hydrolysis (Chawla and Amiji, 2002). The 
polymer has been approved for use in human beings by the United States Food and 
Drug Administration (FDA) (Azimi et al., 2014). 
Thus, PCL was selected as the polymer to prepare the NPs for the present study 
because of its numerous advantages that include biocompatibility, biodegradability, 
non-toxicity, high permeability to small drug molecules, high encapsulation 
efficiency, and does not generate an acidic environment during degradation as 
compared to polylactides and glycolides. The polymer undergoes degradation in a slow 
manner, a property desirable for prolong delivery systems (Koleske, 1978; Murthy, 
1997; Ranjha et al., 2009; V.R. Sinha et al., 2004), and many varieties of APIs have 
been encapsulated or entrapped in the polymer for controlled drug release as well as 
targeted drug delivery (V.R. Sinha et al., 2004). 
 
